Document Classification

Section Type: RESULTS

Text: The proportions of patients with defined endpoints for placebo and LY334370 20, 60, and 200 mg, respectively, were : sustained response, two of 26 (8 %), three of 22 (14 %), 11 of 30 (37 %), and 11 of 21 (52 %) (dose response p < 0. 001) ; response, five of 26 (19 %), four of 22 (18 %), 15 of 30 (50 %), and 15 of 21 (71 %) (p < 0. 001) ; pain free, one of 26 (4 %), none of 22, eight of 30 (27 %), and eight of 21 (38 %) (p = 0. 001) ; sustained pain free, one of 26 (4 %), none of 22, seven of 30 (23 %), and seven of 21 (33 %) (p = 0. 002) ; recurrence rates, one of five (20 %), none of four, four of 15 (27 %), and three of 15 (20 %).